Take a look at the top midday traders.

Peloton – Shares tumbled 12% after the equipment maker disclosed it’s piling up excess inventory and burning through cash in a disappointing earnings report. Peloton issued an even more dim fourth-quarter fiscal sales outlook, and it expects that a price increase may result in some customers being dropped.

Novavax – Shares fell 2% after the vaccine maker missed top and bottom line estimates for its latest quarter. Novavax made its first profit quarter in this quarter. It also reiterated the company’s prior revenue forecast for 2022, and anticipates that sales of vaccines will increase during this quarter.

Vroom – The online used-vehicle seller saw shares popped 19% after posting a narrower-than-expected quarterly loss and better-than-expected revenue. Vroom also revealed that Thomas Shortt will be chief operating officer.

BioHaven Pharmaceutical – Shares of the drugmaker surged nearly 70% after Pfizer announced a dealBioHaven’s main product is the Nurtec migraine pill. Pfizer’s shares were down less than 1 percent.

Upstart – Shares of the AI lending platform plummetedEven with better-than expected quarterly results, nearly 59% of respondents were disappointed. Upstart has lowered its full year outlook because of rising interest rates. It expects that this will result in a decrease in loan volume.

AMC Entertainment – The stock fell 6.7% after the movie theater operator posted a smaller-than-expected quarterly lossAs well as revenue exceeding analyst expectations. AMC saw a boost in revenue per patron due to the success of big-budget films like “The Batman.”

Palantir – Shares of Palantir dropped 4% on Tuesday, extending a 21% decline from Monday that came on the heels of a disappointing first-quarter report with weak guidance. RBC Capital Markets downgraded PalantirTo underperform means that the company will have difficulty achieving its revenue growth targets.

Sunrun – The solar company’s shares fell more than 8% after KeyBanc downgraded the stock to a sector weight rating from overweight. It cited the “significant uncertainty” resulting from KeyBanc’s recent decision regarding net-metering reform. [California].”

— CNBC’s Jesse Pound and Sarah Min contributed reporting